US · Healthcare · Biotechnology
EPS came in at -0.43 against a street estimate of -0.25 — a miss of 72.0%.
Analysts rate Monte Rosa Therapeutics Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $26.88.
| Fund | Stake |
|---|---|
| T. Rowe Price Associates, Inc. | 11.28% |
| NEA Management Company, LLC | 9.79% |
| BlackRock Inc | 8.71% |
| TCG Crossover Management, LLC | 5.88% |
| Vestal Point Capital LP | 5.86% |
| Bvf Inc | 5.68% |
| Baker Bros Advisors LP | 5.53% |
| State Street Corp | 4.75% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader targeting NLRP3/I | 2026-10-01 |
| Reg FD disclosure · Q3 2026 MONTE ROSA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Monte Rosa announced achievement of a Phase 2 clinical study initiation milestone for | 2026-09-08 |
| Quarterly report · Q2 2026 MONTE ROSA THERAPEUTICS, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $621.1 million as of June 30, 2026 ($129.9 mil | 2026-08-06 |
| Results announced · Q3 2026 MONTE ROSA THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $626.0 million (cash, cash equivalents, restricted cash, | 2026-08-06 |
| Shareholder vote results · Q2 2026 MONTE ROSA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of April 16, 2026: 84,382,573 common shares • Stock ticker: GLU | 2026-06-11 |
| Quarterly report · Q1 2026 MONTE ROSA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Loss Q1 2026: $44.5 million (vs. net income of $46.9 million in Q1 2025) | 2026-05-07 |
| Results announced · Q2 2026 MONTE ROSA THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $671.2 million in cash, cash equivalents, restricted cas | 2026-05-07 |
| Proxy statement · Q2 2026 MONTE ROSA THERAPEUTICS, INC. - PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Class II Directors - Three | 2026-04-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Monte Rosa Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.